Open AccessNAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization
Author(s) -
Clemens Schotten,
Lars P. Bechmann,
Paul Manka,
Jens Theysohn,
Alexander Dechêne,
Amr El Fouly,
Francesco Barbato,
Ursula Neumann,
Sonia Radünz,
Svenja Sydor,
Dominik Heider,
Marino Venerito,
Ali Canbay,
Guido Gerken,
Ken Herrmann,
Heiner Wedemeyer,
Jan Best
Publication year - 2019
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000501484
Subject(s) - medicine , hepatocellular carcinoma , nonalcoholic fatty liver disease , interquartile range , gastroenterology , liver function , adverse effect , retrospective cohort study , sorafenib , fatty liver , disease
Patients with advanced hepatocellular carcinoma (HCC) arising in nonalcoholic fatty liver disease (NAFLD) may not be suitable for systemic therapy due to metabolic syndrome-related diseases. Recent trials did not show a survival benefit of radioembolization (RE) compared to sorafenib in advanced stage HCC but RE may represent an adequate alternative in patients with contraindications to systemic therapy due to its favorable safety profile.